60 Degrees Pharmaceuticals opens site for chronic babesiosis study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
November 21, 2025 8:01 AM EST90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatmentStudy will run approximately 12 months and enroll up to 100 patientsInternal estimates of the unmet medical need are between 4,400 and 190,000 cases annually, with no existing FDA-approved treatment for babesiosis
WASHINGTON, Nov. 21, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals,... More
